Year |
Citation |
Score |
2023 |
Baughn LB, Jessen E, Sharma N, Tang H, Smadbeck JB, Long MD, Pearce K, Smith M, Dasari S, Sachs Z, Linden MA, Cook J, Keith Stewart A, Chesi M, Mitra A, et al. Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma. Blood Cancer Journal. 13: 84. PMID 37217482 DOI: 10.1038/s41408-023-00851-5 |
0.624 |
|
2020 |
Walton K, Fernandez MR, Sagatys EM, Reff J, Kim J, Lee MC, Kiluk J, Hui JYC, McKenna D, Hupp M, Forster C, Linden MA, Lawrence NJ, Lawrence HR, Pidala J, et al. Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. Jci Insight. PMID 32255769 DOI: 10.1172/Jci.Insight.136437 |
0.304 |
|
2019 |
Sachs K, Sarver AL, Noble-Orcutt KE, LaRue RS, Antony ML, Chang D, Lee Y, Navis CM, Hillesheim AL, Nykaza IR, Ha NA, Hansen CJ, Karadag FK, Bergerson RJ, Verneris MR, ... ... Linden MA, et al. Single-cell gene expression analyses reveal distinct self-renewing and proliferating subsets in the leukemia stem cell compartment in acute myeloid leukemia. Cancer Research. PMID 31784425 DOI: 10.1158/0008-5472.Can-18-2932 |
0.362 |
|
2019 |
Courville EL, Yohe S, Shivers P, Linden MA. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months. American Journal of Clinical Pathology. PMID 31679012 DOI: 10.1093/Ajcp/Aqz153 |
0.33 |
|
2019 |
Lou E, Vogel RI, Hoostal S, Wong P, Grad A, Monu M, Łukaszewski T, Deshpande J, Dickson EL, Klein M, Linden MA, Subramanian S, Teoh D, Geller MA. Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study. The Oncologist. PMID 31346130 DOI: 10.1634/Theoncologist.2019-0497 |
0.338 |
|
2019 |
Lou E, Vogel RI, Hoostal S, Klein M, Linden MA, Teoh D, Geller MA. Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. Jama Oncology. PMID 31152668 DOI: 10.1001/Jamaoncol.2019.1943 |
0.314 |
|
2019 |
Lou E, Vogel RI, Hoostal S, Grad A, Monu M, Lukaszewski T, Deshpande J, Linden M, Klein M, Teoh DGK, Geller MA. Tumor stroma proportion to predict platinum chemoresistance in primary ovarian carcinomas: A prospective study. Journal of Clinical Oncology. 37: 5581-5581. DOI: 10.1200/Jco.2019.37.15_Suppl.5581 |
0.313 |
|
2018 |
Rahrmann EP, Wolf NK, Otto GM, Heltemes Harris L, Ramsey LB, Shu J, LaRue RS, Linden MA, Rathe SK, Starr TK, Farrar MA, Moriarity BS, Largaespada DA. Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma. Molecular Cancer Research : McR. PMID 30355676 DOI: 10.1158/1541-7786.Mcr-18-0582 |
0.366 |
|
2018 |
How J, Vij KR, Ebadi M, DeFor TE, Romee R, Dolan MM, Ustun C, Weisdorf DJ, Linden MA, Rashidi A. Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. American Journal of Hematology. PMID 30144151 DOI: 10.1002/Ajh.25262 |
0.312 |
|
2017 |
Rashidi A, Linden MA, Percival ME, Sandmaier BM, Devine S, Weisdorf DJ. Recommendations for reporting post-transplant relapse in AML. Bone Marrow Transplantation. PMID 29084204 DOI: 10.1038/Bmt.2017.227 |
0.326 |
|
2017 |
Rashidi A, Linden MA, DeFor TE, Warlick E, Bejanyan N, Yohe S, Weisdorf DJ, Ustun C. History of consolidation is prognostic in AML patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. American Journal of Hematology. PMID 28646534 DOI: 10.1002/Ajh.24834 |
0.316 |
|
2017 |
Baughn LB, Linden MA. Standardization of Minimal Residual Disease Testing in Multiple Myeloma The Journal of Applied Laboratory Medicine: An Aacc Publication. 2: 118-122. DOI: 10.1373/Jalm.2016.020883 |
0.339 |
|
2017 |
Noble-Orcutt KE, Sachs K, Navis C, Hillesheim A, Nykaza I, LaRue RS, Hansen C, Ha N, Linden MA, Largaespada DA, Sachs Z. Abstract PR09: Single-cell transcriptional profiling of acute myeloid leukemia identifies self-renewing stem cells Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Pr09 |
0.378 |
|
2016 |
Baughn LB, Sachs Z, Noble-Orcutt KE, Mitra A, Van Ness BG, Linden MA. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. Leukemia & Lymphoma. 1-10. PMID 27981867 DOI: 10.1080/10428194.2016.1266621 |
0.675 |
|
2016 |
Seelig DM, Ito D, Forster CL, Yoon UA, Breen M, Burns LJ, Bachanova V, Lindblad-Toh K, O'Brien TD, Schmechel SC, Rizzardi AE, Modiano JF, Linden MA. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. Leukemia & Lymphoma. 1-9. PMID 27931134 DOI: 10.1080/10428194.2016.1260122 |
0.365 |
|
2016 |
He F, Horny HP, Boone J, Raza A, Griffith M, Hurley P, Dolan M, Cayci Z, Linden MA, McKenna R, Ustun C. Anaplastic mast cell sarcoma: a unique pathologic entity in mastocytosis. Leukemia & Lymphoma. 1-3. PMID 27808598 DOI: 10.1080/10428194.2016.1250265 |
0.347 |
|
2016 |
Lu H, Bhoopatiraju S, Wang H, Schmitz NP, Wang X, Freeman MJ, Forster CL, Verneris MR, Linden MA, Hallstrom TC. Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. Oncotarget. PMID 27738314 DOI: 10.18632/Oncotarget.12583 |
0.303 |
|
2016 |
Linden MA, Williams SA, Forster C, Croonquist P, Braido J, Danneman S, Beckel M, Callahan M, Seelig D. CLINICAL CHALLENGE. Journal of Zoo and Wildlife Medicine : Official Publication of the American Association of Zoo Veterinarians. 47: 948-951. PMID 27691964 DOI: 10.1638/2015-0178.1 |
0.703 |
|
2016 |
He F, Ha K, Cayci Z, Swenson ME, Caramori L, Amin K, Linden MA, Ustun C. Encapsulated relapsed flt3+AML (myeloid sarcoma) and hurthle cell adenoma presenting in composite: unlikely partners. American Journal of Hematology. PMID 27643393 DOI: 10.1002/Ajh.24558 |
0.326 |
|
2016 |
Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Kanakry CG, Gruhn B, Devine B, Walter RB. The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis Blood. 128: 2842-2842. DOI: 10.1182/Blood.V128.22.2842.2842 |
0.304 |
|
2015 |
Ustun C, Courville EL, DeFor T, Dolan M, Randall N, Yohe S, Bejanyan N, Warlick E, Brunstein C, Weisdorf DJ, Linden MA. Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26551635 DOI: 10.1016/J.Bbmt.2015.10.024 |
0.318 |
|
2015 |
Xie C, Lu H, Nomura A, Hanse EA, Forster CL, Parker JB, Linden MA, Karasch C, Hallstrom TC. Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas. Molecular Cancer. 14: 93. PMID 25907958 DOI: 10.1186/S12943-015-0360-Y |
0.323 |
|
2014 |
Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. Journal of Cancer. 5: 720-7. PMID 25368671 DOI: 10.7150/Jca.9864 |
0.767 |
|
2014 |
Patel SS, Aasen GA, Dolan MM, Linden MA, McKenna RW, Rudrapatna VK, Trottier BJ, Drawz SM. Early diagnosis of intravascular large B-cell lymphoma: clues from routine blood smear morphologic findings. Laboratory Medicine. 45: 248-52. PMID 25051078 DOI: 10.1309/Lmsveokln18M5Xtv |
0.372 |
|
2014 |
Khan F, Linden MA, Zantek ND, Vercellotti GM. Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation Transfusion Medicine. 24: 187-188. PMID 24809981 DOI: 10.1111/Tme.12121 |
0.347 |
|
2014 |
Stessman HA, Mansoor A, Linden MA, Van Ness B, Baughn LB. Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency. Leukemia & Lymphoma. 55: 220-2. PMID 23734619 DOI: 10.3109/10428194.2013.797575 |
0.721 |
|
2014 |
Mitra AK, Stessman H, Linden MA, Van Ness B. Single-Cell Transcriptomics Identifies Intra-Tumor Heterogeneity in Human Myeloma Cell Lines Blood. 124: 3385-3385. DOI: 10.1182/Blood.V124.21.3385.3385 |
0.729 |
|
2013 |
Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. Plos One. 8: e77608. PMID 24204892 DOI: 10.1371/Journal.Pone.0077608 |
0.773 |
|
2013 |
Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, Burke M, Warlick E, Miller JS, Weisdorf D. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplantation. 48: 1415-20. PMID 23933764 DOI: 10.1038/Bmt.2013.124 |
0.319 |
|
2013 |
Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C. How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. American Journal of Hematology. 88: 826-7. PMID 23737091 DOI: 10.1002/Ajh.23497 |
0.307 |
|
2013 |
Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 27: 2075-7. PMID 23728080 DOI: 10.1038/Leu.2013.148 |
0.751 |
|
2013 |
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Molecular Cancer Therapeutics. 12: 1140-50. PMID 23536725 DOI: 10.1158/1535-7163.Mct-12-1151 |
0.77 |
|
2013 |
Lunde LE, Chuang C, Linden MA, Williams SA, Sachs Z, Cayci Z, Young JA, Ustun C. Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction. American Journal of Hematology. 88: 329-32. PMID 22791390 DOI: 10.1002/Ajh.23290 |
0.327 |
|
2013 |
Linden MA, Bachanova V, Sachs Z, Young JA, Singleton TP, Ustun C. Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. Leukemia & Lymphoma. 54: 174-6. PMID 22568510 DOI: 10.3109/10428194.2012.691484 |
0.379 |
|
2013 |
Conway AB, Kaufman SC, Rudrapatna VK, Linden MA. Crystallizing immunoglobulin presenting as polychromatic crystalline keratopathy: An unusual clinical presentation of monoclonal gammopathy of undetermined significance (MGUS) Laboratory Medicine. 44: 344-347. DOI: 10.1309/Lmg2Fh0J2Yineumm |
0.326 |
|
2013 |
Khan F, Linden MA, Zantek ND, Vercellotti GM. Bortezomib Is Highly Effective For Pure Red Cell Aplasia After ABO-Incompatible Hematopoietic Stem Cell Transplantation Blood. 122: 5495-5495. DOI: 10.1182/Blood.V122.21.5495.5495 |
0.354 |
|
2012 |
Linden M, Gopal A, Edlefsen K. Acute appendicitis in a man undergoing therapy for mantle cell lymphoma. Case Reports in Hematology. 2012: 868151. PMID 22953079 DOI: 10.1155/2012/868151 |
0.317 |
|
2012 |
Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Experimental Hematology. 40: 216-27. PMID 22120021 DOI: 10.1016/J.Exphem.2011.11.006 |
0.643 |
|
2005 |
Linden M, Kirchhof N, Kvitrud M, Ness BV. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-XL transgenic mice Leukemia Research. 29: 435-444. PMID 15725478 DOI: 10.1016/J.Leukres.2004.09.007 |
0.361 |
|
2004 |
Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. The Journal of Clinical Investigation. 113: 1763-73. PMID 15199411 DOI: 10.1172/Jci20369 |
0.714 |
|
2004 |
Linden MA, Kirchhof N, Van Ness BG. Targeted Overexpression of Mutant Activated N-ras Leads to Aberrant Plasma Cell Biology. Blood. 104: 1416-1416. DOI: 10.1182/Blood.V104.11.1416.1416 |
0.365 |
|
2003 |
Linden M, Kirchhof N, Carlson C, Van Ness B. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 103: 2779-86. PMID 14656874 DOI: 10.1182/Blood-2003-10-3399 |
0.66 |
|
2003 |
Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood. 102: 2581-92. PMID 12791645 DOI: 10.1182/Blood-2003-04-1227 |
0.727 |
|
2001 |
Liu X, Linden M, Van Ness B. Induced kappa receptor editing shows no allelic preference in a mouse pre-B cell line. Journal of Immunology (Baltimore, Md. : 1950). 165: 7058-63. PMID 11120834 DOI: 10.4049/Jimmunol.165.12.7058 |
0.321 |
|
Show low-probability matches. |